deltatrials
Completed PHASE2/PHASE3 NCT00045877

Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments

Sponsor: Chiron Corporation

Conditions Lymphoma, Non-Hodgkin
Interventions Recombinant Human Interleukin-2 and Rituximab
Updated 5 times since 2017 Last updated: Feb 2, 2006

A PHASE2/PHASE3 clinical study on Lymphoma, Non-Hodgkin, this trial is completed. The trial is conducted by Chiron Corporation and has accumulated 5 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chiron Corporation
Data source: Chiron Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bakersfield, United States, Bloomington, United States, Buffalo, United States, Burlington, United States, Canton, United States, Chicago, United States, Cleveland, United States, Columbus, United States, Fresno, United States, Fullerton, United States and 49 more location s